CNE 201: Children's Oncology Group Clinical Trials Nursing
The Children's Oncology Group Clinical Trials Nursing is online continuing education in individual modules that focuses on emerging finding from clinical trials and best practice for pediatric oncology nursing. The content will include current evidence-based practice for pediatric patients. Learners will have an opportunity to acquire knowledge for nursing practice at the bedside or in the clinic.
This course is offered as one course with 5 modules, or five courses with 1 module.
Nurses, specialty nurses, healthcare providers, and APRNs. Learners should have knowledge of pediatric oncology practice.
In support of improving patient care, the University of Minnesota, Interprofessional Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This course is awarded up to 5.0 ANCC contact hours or each module is awarded 1.0 ANCC contact hour.
Other Health Professionals: It is the responsibility of each participant to determine if the program meets the criteria for re-licensure or re-certification for their discipline. Each participant will receive an Evidence of Participation document. Please check with your accrediting organization for complete requirements.
Successful Completion of Course
Participants must have completed the following:
- Accessed and completed the content found in each module.
- Passed each quiz with at least 80%.
- Completed each module evaluation.
- Completed the course evaluation.
Full Course Registration: $100
Single Module Registration: $25
Cancellation Policy: A course registration may be canceled by emailing the School of Nursing Office of Continuing Professional Development at email@example.com. No refunds will be granted once the Moodle course has been accessed.
Casey Hooke, PhD, RN, PCNS, CPON
Assistant Professor | University of Minnesota
Sue Zupanec, RN, MN, NP
Pediatrics Chair of Nursing Education Sub-Committee | Children's Oncology Group (COG)
Past Chair, COG Nursing Education Sub-Committee | COG Nursing Discipline Steering Committee
Wendy Landier, PhD, RN, CPNP, CPON
Kathy Ruccione, PhD, RN, MPH
Genevieve Sylvain, RN, CPHON and Karla Wilson, RN, MSN, FNP-C, CPON
Faye Willen, RN, MSN, CPNP, CPON and Ruth Anne Herring, RN, MSN, CPNP, CPHON
Jennifer Wofford, RN, PPNP-BC, CPHON and Amy Newman, RN, MSN, CPNP-PC
Learning Objectives & Syllabus
Learning Objectives & Syllabus
Upon completion of the module/course, the learners will be able to:
- Describe nursing assessments and interventions for pediatric cancer patients receiving new protocol-based therapies.
- Identify strategies for supporting patients and families after completing treatment in receiving comprehensive follow up care and information.
- Identify nursing strategies for promoting adherence to cancer treatment.
Module A - Hodgkin Lymphoma Evolution through Revolution: Transitioning toward Targeted Therapy
- Discuss Hodgkin lymphoma and identify previous treatment strategies.
- Describe the Childhood Hodgkin Lymphoma staging system.
- Discuss treatment strategies for high-risk Hodgkin lymphoma.
Module B - Late Effects and Clinical Trials
- Identify actual or potential late effects related to cancer treatment in children, adolescents, and young adults treated on COG protocols.
- Discuss strategies to identify early indicators of late effects and appropriate health care interventions.
- Describe current COG research studies focusing on late effects of treatment.
Module C - What Happened to My Clinical Trial? How to Help Patients and Families Get Results
- Discuss ethical principles that underlie informing patients and families of clinical trial results.
- Explain the evolution of return of results (ROR) plan within the cooperative group.
- Strategize about the the nurse's role in supporting patients and families in the return of results process.
Module D - Novel Therapeutics in Advancing Pediatric Oncology in COG
- Define what constitutes a Phase 1/2/3 trial and define what is a novel/investigational event.
- Describe three potential side effects of crizotinib and blinatumomab and identify the nursing interventions unique to each particular drug.
- Describe three potential side effects of timsirolimus and pazopanib.
Module E - Innovation, Communication, Motivation: Keys to Adherence
- Identify two challenges to adherence that families may face when children are taking oral chemotherapy at home during the maintenance of A.L.L. therapy.
- List three factors that may facilitate adherence to oral chemotherapy in children with A.L.L.
- Describe innovations currently in progress within the COG clinical trials to improve medication adherence.